NASDAQ:NAGE
Niagen Bioscience, Inc.
Niagen Bioscience, Inc.'s revenue grew 29.9% in fiscal 2025 to $129.4M while operating margin rose to 12.6%, its highest in 9 years. The diluted share count rose 9.4%.Summary generated from Niagen Bioscience, Inc.'s SEC filings. Latest annual report filed Mar 4, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$129.4M
Revenue growth+29.9%
Revenue, 5-yr CAGR+16.9%
Gross margin64.3%
Operating margin12.6%
Net margin13.4%
ROICn/a
Return on equity28.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+9.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 67 | 72 | 84 | 100 | 129 |
| Operating income | −27 | −19 | −6 | 8 | 16 |
| Net income | −27 | −17 | −5 | 9 | 17 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 4Insider transaction report
Jul 8, 2026 - 4Insider transaction report
Jul 8, 2026 - 8-KResults of a shareholder vote
Jun 29, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - DEF 14AProxy statement
Apr 29, 2026